Sign inJoin waitlistJoin the waitlist

Gitanjali Srivastava

Program Director, Obesity Medicine Fellowship · Vanderbilt Health

Credentials: · · · · · · · · ·

History

Obesity Medicine Fellowship · Vanderbilt Health
Present
Obesity Medicine · Vanderbilt Health
Present
Vanderbilt Weight Loss Clinics · Vanderbilt Health
Present

Louisiana State University School of Medicine in New Orleans
2003

Research

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
Nature Medicine · 2023 · 366 citations
Current pharmacotherapy for obesity
Review · Nature Reviews Endocrinology · 2018 · First of 2 authors · 279 citations
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Review · Current Obesity Reports · 2018 · First of 2 authors · 150 citations

Jason Samuels
7 papers · 7 as a fellow
Caroline Apovian
6 papers
Fatima Stanford
4 papers
Gunther Wong
4 papers
NP
Nina Paddu
4 papers · 2 as a resident
Brandon Williams
3 papers · 2 as a resident
Erica Garner
3 papers · 3 as a fellow
LK
Lee Kaplan
3 papers
Matthew Spann
3 papers
Trent Rosenbloom
3 papers
Vance Albaugh
3 papers
WE
Wayne English
3 papers

Clinical trials

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2030
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2032
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2024–2027